Skip to main content

MediWound Ltd.

corporate_fare Company Profile

MediWound Ltd.

MDWD·NASDAQ·Life Sciences·CIK 0001593984

MediWound Ltd. is a biopharmaceutical company that develops, manufactures, and sells new biological and non-surgical treatments for tissue repair and regeneration. The company operates in the United States, Germany, Italy, Spain, and other international markets. MediWound's primary commercial product is NexoBrid, a biopharmaceutical used to remove dead tissue (eschar) from patients with deep partial- and full-thickness thermal burns. This product is sold to burn centers and hospital burn units. The company is also developing EscharEx, an enzymatic therapy based on bromelain, intended for treating chronic and other difficult-to-heal wounds. Additionally, MediWound is developing MW005, a biological product candidate applied topically to treat non-melanoma skin cancers. MediWound Ltd. was founded in 2000 and has its headquarters in Yavne, Israel.

MediWound Ltd. (NASDAQ:MDWD) is a publicly traded company in the Life Sciences sector. Wiseek monitors MDWD SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Key EscharEx Phase III Trial Delayed by a Quarter; MediWound Q1 Revenue Missed Estimates
  • MediWound Q1 Revenue Misses by Over 50%, Citing BARDA Timing and Conflict
  • MediWound Reports Q1 Revenue Miss, Increased Losses, and Delays in Key Clinical Trial and Manufacturing
  • MediWound Forecasts 65-Cent Loss, 21% Revenue Drop Ahead of Q1 Report
  • Up to $197M BARDA Contract Awarded to Vericel for MediWound's NexoBrid

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$16.96M
Net Income
-$23.88M
Diluted EPS
-$2.10
Op. Cash Flow
-$16.12M
Free Cash Flow
-$21.63M
Gross Profit
$3.25M
Operating Income
-$25.27M
Cash & Equivalents
$4.8M
Debt / Equity
0.00×
Net Margin
-140.8%
Shares Outstanding
12.84M sh
Source: 20-F · filed 2026-03-05 · accession 0001178913-26-000749

Insider Transactions

MDWD files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with M →
$14.22
52-week range · as of 2026-05-27 $14.9 – $22.5
Market cap
$182.67M
Volume
48K (0.5× avg)
3-mo avg 99.2K
Live data · 2026-06-14 06:08 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MDWD - Latest Insights

MDWD
May 28, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
8
Key EscharEx Phase III Trial Delayed by a Quarter; MediWound Q1 Revenue Missed Estimates
Price at Filing: $14.33
Real-time Price: $14.22 info
Change: -$0.110 (-0.77%) info
Market Cap: $182.665M info
Sentiment: Negative
View Wiseek Article
MDWD
May 27, 2026, 7:08 AM EDT
Source: Reuters
Importance Score:
7
MediWound Q1 Revenue Misses by Over 50%, Citing BARDA Timing and Conflict
Price at Filing: $16.68
Real-time Price: $14.22 info
Change: -$2.46 (-15%) info
Market Cap: $182.665M info
Sentiment: Negative
View Wiseek Article
MDWD
May 27, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
8
MediWound Reports Q1 Revenue Miss, Increased Losses, and Delays in Key Clinical Trial and Manufacturing
Price at Filing: $16.68
Real-time Price: $14.22 info
Change: -$2.46 (-15%) info
Market Cap: $182.665M info
Sentiment: Negative
View Wiseek Article
MDWD
May 25, 2026, 8:32 AM EDT
Source: Reuters
Importance Score:
7
MediWound Forecasts 65-Cent Loss, 21% Revenue Drop Ahead of Q1 Report
Price at Filing: $16.58
Real-time Price: $14.22 info
Change: -$2.36 (-14%) info
Market Cap: $182.665M info
Sentiment: Negative
View Wiseek Article
MDWD
Apr 02, 2026, 3:26 PM EDT
Source: GlobeNewswire
Importance Score:
9
Up to $197M BARDA Contract Awarded to Vericel for MediWound's NexoBrid
Price at Filing: $16.92
Real-time Price: $14.22 info
Change: -$2.70 (-16%) info
Market Cap: $182.665M info
Sentiment: Positive
View Wiseek Article
MDWD
Mar 05, 2026, 7:30 AM EST
Filing Type: 20-F
Importance Score:
8
MediWound Reports Mixed FY2025 Financials, Advances EscharEx Phase III, Expands NexoBrid Manufacturing, and Details Geopolitical Risks
Price at Filing: $17.20
Real-time Price: $14.22 info
Change: -$2.98 (-17%) info
Market Cap: $182.665M info
Sentiment: Neutral
View Wiseek Article
MDWD
Mar 05, 2026, 7:07 AM EST
Source: Dow Jones Newswires
Importance Score:
7
MediWound Projects $32M-$35M Revenue for 2027
Price at Filing: $17.20
Real-time Price: $14.22 info
Change: -$2.98 (-17%) info
Market Cap: $182.665M info
Sentiment: Neutral
View Wiseek Article
MDWD
Mar 05, 2026, 7:05 AM EST
Filing Type: 6-K
Importance Score:
7
MediWound Reports Mixed Q4/FY25 Results, Reaffirms 2026-2028 Guidance, Boosts Cash Position
Price at Filing: $17.20
Real-time Price: $14.22 info
Change: -$2.98 (-17%) info
Market Cap: $182.665M info
Sentiment: Neutral
View Wiseek Article
MDWD
Feb 19, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
7
Shareholders Approve 300,000 Share Increase for Incentive Plan
Price at Filing: $17.27
Real-time Price: $14.22 info
Change: -$3.05 (-18%) info
Market Cap: $182.665M info
Sentiment: Neutral
View Wiseek Article
MDWD
Jan 15, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
7
MediWound seeks shareholder approval to increase equity incentive plan by 300,000 shares
Price at Filing: $17.37
Real-time Price: $14.22 info
Change: -$3.15 (-18%) info
Market Cap: $182.665M info
Sentiment: Negative
View Wiseek Article
MDWD
Jan 12, 2026, 7:08 AM EST
Filing Type: 6-K
Importance Score:
7
MediWound Projects Strong Revenue Growth Through 2028, Provides Positive Clinical & Operational Updates
Price at Filing: $19.30
Real-time Price: $14.22 info
Change: -$5.08 (-26%) info
Market Cap: $182.665M info
Sentiment: Positive
View Wiseek Article